Lupus & antiphospholipid syndrome
Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)
Authors' conclusion
We demonstrated the antiplatelet effects of HCQ under conditions simulating the physiological environment by using T-TAS and identified the range of doses at which HCQ exerted antiplatelet effects.
Study context
- Population
- Patients with SLE, single centre
- Participants
- 57 patients
- Exposure
- Hydroxychloroquine (HCQ)/RBW ≥5 mg/kg vs <5 mg/kg
- Outcome
- Thrombogenicity by T-TAS: area under the pressure curve for 10 min (PL-AUC10) and time to 10 kPa (T10)
Methodological detailssingle-centre, in vitro study on healthy donor blood samples
- Single-centre
- In vitro study on healthy donor blood samples
Main finding
As reported in the abstract
T-TAS thrombogenicity by HCQ dose
- PL-AUC10 significantly lower in HCQ/RBW ≥5 mg/kg than <5 mg/kg
- T10 similar between groups
- Antiplatelet effects first detected at HCQ/RBW of ≈4 mg/kg
- Antiplatelet effects reached a plateau at around 5.5 mg/kg
- HCQ/RBW >4.6 mg/kg clearly exerted antiplatelet effects
Observational data: associations, not effects.
Further findings
In vitro (healthy donor blood): T-TAS thrombus formation and platelet aggregation to epinephrine
- HCQ inhibited thrombus formation in T-TAS and epinephrine-induced platelet aggregation dose-dependently
Original publication
Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS). Lupus Sci Med. Published 8 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →